Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
Rhea-AI Summary
Equillium (Nasdaq: EQ), a biotechnology firm, will participate in the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 20, 2020. The discussion will include CEO Bruce Steel and CMO Krishna Polu, starting at 3:05 PM ET. The event will be broadcast live, and replays will be available for 30 days. Equillium is focused on developing itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at treating severe autoimmune and inflammatory disorders.
Positive
- None.
Negative
- None.
News Market Reaction – EQ
On the day this news was published, EQ gained 11.07%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., chief medical officer, will participate in a fireside discussion at 2020 RBC Capital Markets Virtual Global Healthcare Conference on Wednesday, May 20, 2020.
| Date: | Wednesday, May 20, 2020 |
| Time: | 3:05 PM Eastern Time | 12:05 PM Pacific Time |
| Location: | Virtual Webcast |
Live webcasts of both presentations will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/. Replays will be available for 30 days following each webcast.
About Equillium
Equillium is a clinical biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Equillium’s initial product candidate, itolizumab (EQ001), is a clinical-stage, first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases. Itolizumab is a clinically-validated therapeutic that has demonstrated a favorable safety and tolerability profile. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited. Equillium believes that itolizumab has the potential to be a best-in-class disease modifying therapeutic and is advancing itolizumab into clinical development in the following severe immuno-inflammatory disorders: uncontrolled asthma, acute graft-versus-host disease, and lupus nephritis. For more information, visit www.equilliumbio.com.
Investor Contact
+1-858-412-5302
ir@equilliumbio.com
Media Contact
Cammy Duong
Canale Communications
+1-619-849-5389
cammy@canalecomm.com
FAQ
What event will Equillium participate in on May 20, 2020?
Who will represent Equillium at the RBC Capital Markets Conference?
What time does Equillium's discussion start at the conference?
Where can I watch the Equillium conference presentation?
What is itolizumab and its significance for Equillium?
